Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots ...

People who take an anticoagulant medicine double their risk of an internal bleed if they take a type of painkiller called a ...

Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla., Nov. 19, ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots ...

Maxim Group analyst Naz Rahman has reiterated their bullish stance on TLPH stock, giving a Buy rating on November 14. Naz Rahman has given his ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to preliminary ...

DOACs only and warfarin only are more likely to be prescribed to Medicare beneficiaries seeing clinicians in rural areas compared with urban areas.

The use of anticoagulants offers significant benefits. They are indicated for various uses depending on the specific ...

However, there has been a lack of research on the impact of early compared to delayed anticoagulant treatment for AF stroke patients. This is what researchers at University College London (UCL ...

The FDA has granted fast-track status to Bayer's oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs.

Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.

Patients who receive a heart valve replacement are well-known to be at a high risk for stroke, blood clots and deep vein ...